Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Leukemia

  Free Subscription


22.08.2022

1 Am J Hematol
3 Ann Hematol
1 Biochem Biophys Res Commun
7 Blood
1 BMC Cancer
1 Bone Marrow Transplant
1 Cancer Chemother Pharmacol
1 Int J Hematol
1 J Pediatr Hematol Oncol
4 Leuk Lymphoma
2 Leukemia


  Retrieve available abstracts of this week’s articles:
HTML format
 
 
Single Articles


    Am J Hematol

  1. FALINI B
    Acute myeloid leukemia risk models: Where do we stand?
    Am J Hematol. 2022;97:1124-1126.
    PubMed        


    Ann Hematol

  2. YANADA M
    Treatment for relapsed acute promyelocytic leukemia.
    Ann Hematol. 2022 Aug 16. pii: 10.1007/s00277-022-04954.
    PubMed         Abstract available

  3. ZHAI Y, Shang J, Yao W, Wu D, et al
    Successful eradication of central nervous system infiltration of primary plasma cell leukemia by temozolomide.
    Ann Hematol. 2022 Aug 15. pii: 10.1007/s00277-022-04942.
    PubMed        

  4. SPATH C, Schonau M, Gaubert S, Neumann T, et al
    Rhabdomyolysis induced by nelarabine.
    Ann Hematol. 2022;101:2111-2112.
    PubMed        


    Biochem Biophys Res Commun

  5. YANG Y, Liu L, Tucker HO
    Induction of chronic lymphocytic leukemia-like disease in STYK1/NOK transgenic mice.
    Biochem Biophys Res Commun. 2022;626:51-57.
    PubMed         Abstract available


    Blood

  6. CARRATT SA, Kong GL, Curtiss BM, Schonrock Z, et al
    Mutated SETBP1 activates transcription of Myc programs to accelerate CSF3R-driven myeloproliferative neoplasms.
    Blood. 2022;140:644-658.
    PubMed         Abstract available

  7. CUNNINGHAM A, Erdem A, Alshamleh I, Geugien M, et al
    Dietary methionine starvation impairs acute myeloid leukemia progression.
    Blood. 2022 Aug 19. pii: 486352. doi: 10.1182/blood.2022017575.
    PubMed         Abstract available

  8. CAPPELLI LV, Fiore D, Phillip JM, Yoffe L, et al
    Endothelial-leukemia interactions remodel drug responses uncovering T-ALL vulnerabilities.
    Blood. 2022 Aug 18. pii: 486319. doi: 10.1182/blood.2022015414.
    PubMed         Abstract available

  9. WANG J, Chang CY, Yang X, Zhou F, et al
    Leukemia inhibitory factor protects against graft-versus-host disease while preserving graft-versus-leukemia activity.
    Blood. 2022 Aug 18. pii: 486317. doi: 10.1182/blood.2022015677.
    PubMed         Abstract available

  10. WAGNER DL
    The uncut version: base-edited allo-CAR T cells.
    Blood. 2022;140:526-527.
    PubMed        

  11. DEAGLIO S
    Glutamine and CLL: ready for prime time?
    Blood. 2022;140:528-529.
    PubMed        

  12. DIORIO C, Murray R, Naniong M, Barrera L, et al
    Cytosine base editing enables quadruple-edited allogeneic CART cells for T-ALL.
    Blood. 2022;140:619-629.
    PubMed         Abstract available


    BMC Cancer

  13. BAI L, Zhang YZ, Yan CH, Wang Y, et al
    Outcomes of allogeneic haematopoietic stem cell transplantation for paediatric patients with MLL-rearranged acute myeloid leukaemia.
    BMC Cancer. 2022;22:896.
    PubMed         Abstract available


    Bone Marrow Transplant

  14. BARON F, Labopin M, Tischer J, Ciceri F, et al
    Comparison of HLA-mismatched unrelated donor transplantation with post-transplant cyclophosphamide versus HLA-haploidentical transplantation in patients with active acute myeloid leukemia.
    Bone Marrow Transplant. 2022 Aug 17. pii: 10.1038/s41409-022-01781.
    PubMed         Abstract available


    Cancer Chemother Pharmacol

  15. SATO H, Kobayashi T, Fujita N, Yamashita T, et al
    Safe administration and pharmacokinetic monitoring of crushed venetoclax tablets with posaconazole and clarithromycin via percutaneous endoscopic gastrostomy tube in a patient with acute myeloid leukemia.
    Cancer Chemother Pharmacol. 2022 Aug 13. pii: 10.1007/s00280-022-04460.
    PubMed         Abstract available


    Int J Hematol

  16. ONO T, Hino M, Matsumura I, Fujisawa S, et al
    Bosutinib in Japanese patients with newly diagnosed chronic-phase chronic myeloid leukemia: final 3-year follow-up results of a phase 2 study.
    Int J Hematol. 2022 Aug 13. pii: 10.1007/s12185-022-03435.
    PubMed         Abstract available


    J Pediatr Hematol Oncol

  17. XU J, Zhao L
    Polo-like Kinase 4: the Variation During Therapy and its Relation to Treatment Response and Prognostic Risk Stratification in Childhood Acute Lymphoblastic Leukemia Patients.
    J Pediatr Hematol Oncol. 2022 Aug 11. pii: 00043426-990000000-00071.
    PubMed         Abstract available


    Leuk Lymphoma

  18. BASSIG BA, Hu W, Morton LM, Ji BT, et al
    Incidence of myeloid malignancies by subtype in Hong Kong and comparisons with Asian and white men and women in the United States.
    Leuk Lymphoma. 2022;63:1917-1924.
    PubMed         Abstract available

  19. MACARON W, Sargsyan Z, Short NJ
    Hyperleukocytosis and leukostasis in acute and chronic leukemias.
    Leuk Lymphoma. 2022;63:1780-1791.
    PubMed         Abstract available

  20. CHEN EC, Liu Y, Harris CE, Winer ES, et al
    Outcomes of antifungal prophylaxis for newly diagnosed AML patients treated with a hypomethylating agent and venetoclax.
    Leuk Lymphoma. 2022;63:1934-1941.
    PubMed         Abstract available

  21. COZAD M, Stump SE, Buhlinger K, Collins J 4th, et al
    Evaluation of an interdisciplinary venetoclax initiation process in minimizing risk of tumor lysis syndrome.
    Leuk Lymphoma. 2022;63:1831-1838.
    PubMed         Abstract available


    Leukemia

  22. ARNIANI S, Pierini V, Pellanera F, Matteucci C, et al
    Chromothripsis is a frequent event and underlies typical genetic changes in early T-cell precursor lymphoblastic leukemia in adults.
    Leukemia. 2022 Aug 16. pii: 10.1038/s41375-022-01671.
    PubMed         Abstract available

  23. DESPREZ C, Riou J, Peterlin P, Marchand T, et al
    Comparison of scoring systems evaluating suitability for intensive chemotherapy in adults with acute myeloid leukemia-a Grand Ouest Against Leukemia (GOAL) study.
    Leukemia. 2022 Aug 12. pii: 10.1038/s41375-022-01677.
    PubMed         Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Leukemia is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: